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DO CALCIUM CHANNEL BLOCKERS PROTECT AGAINST FIRST DOSE
REACTION TO OKT3? Eric A. Richard, and Margaret J. Bia.

Section of

Nephrology, Department of Internal Medicine, Yale University School
of Medicine, New Haven, CT.

Abstract
OKT3 is a monoclonal antibody used as an immunosuppressant
to treat rejection or to prevent cyclosporine toxicity in the setting
of post-operative delayed graft functioning.

Use of OKT3 is often

complicated by a first dose reaction, ranging from a mild reaction to
a

life

threatening

lymphocytes

complication.

promotes

an

OKT3

influx

of

binding

calcium,

to

which

human

T

stimulates

mitogenesis and a release of lymphokines (the proposed cause of
this clinical syndrome).
T

lymphocyte

determine

Since calcium channel blockers can inhibit

activation

if clinically

in

used

vitro,

this

doses

study

of calcium

was

performed

channel

to

blockers

decrease the severity of first dose reaction to OKT3.
A retrospective, chart review study was employed to analyze
the incidence of side effects of patients on calcium channel blockers
(N=20) as compared to those who were not (N=49).

The calcium

channel blocker group consisted of 13 patients on nifedipine (30120 mg/day), 5 on verapamil (120-480 mg/day), and 2 on diltiazem
(90-180 mg/day).

All patients received OKT3 (5mg) after being

premedicated with acetaminophen, diphenhydramine,
amounts of glucocorticoids.
sex,

race,

percent on

and varying

The two groups were similar in age,

dialysis,

and

percent who

had

received

cadaveric transplants.

Dose

of azathioprine,

dose

of

methyl-

prednisolone, and both the dose and level of cyclosporine were also
similar in the two groups.
There were no differences between the two groups in the
frequency of the fever or the magnitude of the fever spike.

The two

groups were also similar in the frequencies of chills, Gl
hemodynamic changes, and respiratory symptoms.
of

fatigue

was

different,

channel blocker group.
of calcium

channel

occurring

more

often

upset,

Only the symptom
in

the

calcium

The data suggest that clinically used doses

blockers do

not protect against first dose

reaction to OKT3 perhaps because these doses do not achieve plasma
levels

high

enough to

lymphokine release.

inhibit T cell

activation

and

subsequent
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Introduction
The

monoclonal

antibody

OKT3

is

a

powerful

immunosuppressant used in renal transplant patients as therapy to
treat resistant rejection and to avoid cyclosporine nephrotoxicity in
the

clinical

setting

of

post-operative

delayed

graft

functioning.

First and second doses of OKT3 are associated with a well described
clinical syndrome that is known as "first dose reaction to OKT3".
The syndrome consists of fever, chills, hemodynamic changes, Gl
upset,

and

neurological

changes.

Initial

premedication

with

acetaminophen, diphenhydramine and glucocorticoids has not been
able

to

eliminate

this

syndrome.

Although

infrequently

life

threatening, this adverse drug reaction is an important source of
patient discomfort.

This adverse reaction may result from an OKT3

induced T cell activation, leading to the production and release of
lymphokines.

This activation appears to use calcium as a second

messenger, and, in vitro, calcium channel blockers decrease the
production of lymphokines.

This study examines whether clinically

used doses of calcium channel blockers can decrease the first dose
reaction to OKT3.
General Description
Human T cells detect antigen, leading to subsequent activation
and proliferation, via a T cell receptor(TCR)/CD3 complex (1).

Proof

(2)

CD3

that

a

TCR/CD3

complex

exists

includes

that

immunoprecipitates with TCR, CD3 comodulates with TCR, and a
stoichiometric relationship exists between CD3 and TCR.

Consisting

of a and (3 subunits, the TCR recognizes the specific antigen; the CD3

2

subunit,

which

transduces

is

non-covalently

the

linked to the

antigen-binding

signal

TCR

into

3

the

subunit,
T

cell.

Phosphorylation of the CD3 complex post TCR occupancy (3) lends
proof that CD3

is the

signal transducer.

Furthermore,

human

monoclonal antibodies which bind to the CD3 complex induce an
increase in intracellular calcium (2,4), T cell proliferation (2), and
lymphokine production (5,6,7,8) - all similar events to what occurs
after antigen binds to the TCR.

Present on all mature T cells and

late

complex

thymocytes

subunits

-

2

(1),

the

CD3

glycoproteins

(y and 5)

consists
and

1
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invariant

non-glycosylated

hydrophobic polypeptide (e).

Because its intracellular component is

larger than

CD38 is postulated to be the actual

its extracellular,

signal transducer in man.
Initially developed

in

1978 to differentiate

between

T cell

subsets (9), the monoclonal antibody OKT3 binds to a 20kd subunit of
the CD3 complex.
from OKT3.

In fact, the term CD3 was subsequently derived

The first monoclonal antibody used in humans, OKT3 is

an lgG2a immunoglobulin and consists of a 50kd heavy chain and a
25kd light chain.

Derived from a hybridoma and grown as an ascites

in pathogen free, standard bred mice, OKT3 is purified to be free of
both pyrogens and pathogens.
Immunosuppression
OKT3

exerts

its

powerful

immunosuppressive

actions

(10,11,12,13) by removing CD3+ cells from the circulation (usually
within 1 hour) and by blocking the killer function of sessile T cells
(the would be kiiler cells in the allograft) - as described below.

3

After the 0KT3 antibody binds to the CD3 complex, this complex is
opsonized and is either removed by the reticulo-endothelial system
via lysis or redistributed to lymph nodes.

Furthermore, similar to

high levels of antigen, OKT3 effectively modulates, or removes, not
only the CD3 antigen from the T cell surface but also the TCR,
making these T cells non-functional.
Studies by Gebel(14)

have shown that in

renal transplant

patients, circulating CD3 cells are diminished from 70% to <1% after
one dose of OKT3.

Within 2 days, CD3 cells returned to the

circulation with greatly decreased density of the CD3 molecule and
no co-expression of TCR.
stimulation

in

vitro,

immuno-incompetent.

these

Failing to proliferate
CD3-

Because

cells
CD3+

were
cells

post allogenic

nonfunctional
returned

to

and
the

circulation and lymph nodes once OKT3 was stopped, this process
was reversible.

Similarly, Zlabiger(15) and Caillot-Zucman(16), by

showing modulation of CD3 cells, added further evidence for this
phenomenon.

As T cell depletion was only 20-60% in the lymph

nodes, modulation plays a more vital role.

More importantly(17), in

the allograft, some CD3+ cells were present but nonfunctional and
without the TCR.
the

Therefore, because of the effects of modulation,

modulated T cells were

response against the allograft.

incapable of mounting

an

immune

Reappearance of the CD3 complex

may have indicated failure of therapy, perhaps secondary to the
development of anti-OKT3 antibodies.
The inhibition of T cell killing capacity is another powerful
immunosuppressive mechanism of OKT3.

Landegren(18), using cell
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cultures of peripheral blood lymphocytes from healthy volunteers,
showed that OKT3 blocked cytotoxic T cell lysis by impeding the
ability of the cytotoxic T lymphocytes to lyse bound cells, rather
than by reducing target binding.
panel

of anti-CD3

monoclonal

However, Seventer(19), using a
antibodies which

demonstrated that OKT3 inhibited target cell
cytotoxic

T

changes.

lymphocytes

via

steric

Nonetheless,

the

cytotoxic

recognition

hindrance
T

included

or

OKT3,
by the

confirmational

lymphocytes

blocking

capacity occurred in vitro at normal therapeutic trough levels of
lug/ml (for 5mg dose).
Clinical

Trials

Many clinical trials have suggested that OKT3 is successful
when

used

as

treatment

against

rejection

(both

primary

and

resistant) and as prophylaxis in the early post transplant period.
Treating

8

cadaver

renal

allograft

recipients

undergoing

acute

rejection, Cosimi(20) reported on the first clinical trial using OKT3.
This monoclonal antibody offered several advantages over polyclonal
antibodies - mainly homogeneity, ease of use and monitoring, and
lower toxicity.
case

Within 2-7 days, OKT3 reversed rejection in all 8

with a 75% 12 month graft survival.

Similarly, in a large,

prospective, randomized, multicenter study(21),

123 patients were

treated with 14 days of OKT3 vs conventional high dose steroids.
The results showed reversal in 94% vs 75% and 1 year survival at
62% vs 45% (OKT3 vs steroids).

The efficacy of OKT3 in these initial

trials set the stage for use in other transplant settings.

5

Many studies have suggested that 0KT3 is efficacious in the
primary treatment of rejection (22,23) and in the treatment of both
steroid resistant (23,24,26-30) and ATG/steroid resistant rejection
(22,24,30).

Some

investigators(28)

suggested

treating

rejection

with a pulse of high dose steroid; if successful, this obviates the
need for OKT3 therapy.

Some have also shown some success with

OKT3 as a prophylactic agent against rejection (25,34-40) and in the
setting of post-operative delayed graft functioning

(25,31), where

clinicians are

its

nephrotoxicity.

hesitant

to

use cyclosporine with

associated

Researchers (32,33) have used OKT3 concomitantly

with cyclosporine with good success in the treatment of rejection;
in fact, cyclosporine may have reduced the formation of anti-OKT3
antibodies and increased the efficacy of OKT3 (32).
If it has been used as a prophylactic agent against rejection in
the early post-op period, OKT3 can be re-used to treat rejection
episodes (41,42).

Because OKT3 is a murine derived

product,

antibodies to OKT3 can form after initial administration of OKT3.
Presence of low titre anti-OKT3 antibodies does not preclude re¬
treatment with OKT3.

However, the number of doses of OKT3 needed

to deplete CD3 cells from the circulation can be greater in the
retreated patients as compared with first time receivers of OKT3
(41).

Furthermore, it may be necessary to increase the dose of OKT3

in retreatment groups to achieve adequate serum OKT3 levels and to
deplete CD3 cells.

Presence of high titre antibodies is a contra¬

indication to re-use of OKT3(41) as OKT3 is rarely effective in this
situation.
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Side Effects of OKT3
In the first clinical trial (20), which used a small patient
sample of 8 patients, chills, a febrile response and an occasional
wheeze on the first day were noted.

This adverse drug reaction

appeared quite mild and was easily treated with antihistamines and
acetaminophen.

In the multicenter study (21) in 1985, adverse drug

reactions were first recognized as being important.

These reactions

began 45-60 minutes after the first injection (sometimes second,
and never subsequent) and lasted several hours.

Reported

signs and

symptoms included fever (73%), chills (57%), tremor (10%), dyspnea
(21%), chest pain/tightness (14%), wheeze (11%), nausea (11%), and
vomiting (13%).

One patient in a state of fluid overload developed

pulmonary edema.

Because of the timing of these signs and

symptoms after the first or second dose (and rarely subsequent), the
syndrome has been labeled "first dose reaction to OKT3”.
Subsequent studies

(20,22,25,27,34,38,43,44)

have

shown

similar side effects, in addition to others, occurring at significant
rates.

The signs and symptoms that have occurred frequently enough

so that multiple investigators have reported them include fever,
chills,

hemodynamic

sequelae

(tachycardia,

changes

in

blood

pressure), gastro-intestinal upset (vomiting, diarrhea), CNS changes
(headache,
distress

seizure,
(dyspnea,

arthralgias/myalgias.
OKT3-related

malaise,
wheeze,

aseptic

meningitis),

chest

respiratory

pain/tightness)

and

The symptoms of acute rejection can mimic

symptomatology.

Similarly,

OKT3

difficult to distinguish from normal post-op recovery.

reactions

are

7

Fever and chills, respiratory and hemodynamic sequelae are the
most frequent first dose side effects which occur in the first few
hours (43).

Hypertension and mild dyspnea are associated with a

state of relative fluid overload.

This is why many protocols include

a diuresis/dialysis to <103% of ideal body weight prior to OKT3.
Furthermore, hypotension and tachycardia have been associated with
a

state

of

relative

volume

depletion,

often

secondary

to

over

aggressive diuresis and dialysis.
Gastro-intestinal and CNS side effects usually appear between
days 2-3 of OKT3 therapy.

These symptoms are usually transient

and

after

self-limiting

and

stop

OKT3

is

withdrawn..

Aseptic

meningitis with symptoms of headache, fever, photophobia, nuchal
rigidity, and mental status changes (43) has occurred in a small
percentage
elevated

of

patients.

protein,

normal

Lumbar

puncture

glucose,

and

shows

negative

leukocytosis,

cultures.

One

possible cause (45) for aseptic meningitis is that OKT3 cross reacts
with a neural antigen, promoting local inflammation.

Seizures can

also occur, with one study (43) showing an association with post-op
delayed graft functioning.
Mechanism of Reaction to OKT3
From the initial studies, it was suggested that the first dose
reaction was caused by a release of endogenous pyrogens from lysed
T cells (21).

These first dose symptoms were not attributed to

hypersensitivity for the following
almost

all

patients

without

reasons previous

1) they occurred

exposure

to

in

murine

immunoglobulin, 2) skin tests prior to OKT3 were routinely negative,

8

and 3) symptoms did not recur with later injections.
of

the

side

administration

effects
of

were

similar

to

those

(IL-2)

and

after

interleukin-2

Because many
after

systemic

endotoxic

shock

mediated by tumor necrosis factor-a (TNF-a), lymphokines began to
be investigated as the cause of the OKT3 induced clinical syndrome.
Lymphokines are well
inflammatory and

immune

characterized

as

mediators

reactions (12,46,47,48).

of

both

Interleukin-2

(IL-2), produced in T cells and known also as T-cell growth factor,
has been clearly implicated in
differentiation.
reaction

in

Rosenberg

cancer

patients

inducing T cell proliferation

(46)

described

an

who

received

high

adverse
dose

and

clinical

IL-2

with

lymphokine activated cells.

Symptoms reminiscent of OKT3 included

fever,

fatigue,

vomiting,

diarrhea,

and

chills.

Furthermore,

he

described a scenario of increased capillary permeability (leading to
pulmonary edema) and decreased vascular resistance (leading to
hypotension).

In

fact,

34 out of 180 treatment courses were

complicated by pulmonary edema; 16 patients required intubation
(46).
Tumor

necrosis

implicated as a

factor-a (TNF-a), or cachectin,

mediator of

cachexia

in

has been

cancer patients and

endotoxic shock in patients with gram negative sepsis.

Produced by

both monocytes and T cells, TNF-a causes piloerection, diarrhea and
withdrawal in mice, hypotension, tachypnea and respiratory arrest
in rats, and fever in rabbits.

Remick (47) studied the in vivo effects

of human recombinant TNF-a in mice and induced hypovolemic shock,
necrosis

of the

small

bowel,

fever,

hypotension,

malaise,

and

9

respiratory

failure.

Kinkhabwala

(49)

has

shown

activated T cells express TNF-a on their cell surface.
that

cell

bound

inflammatory

TNF,

which

response

and

is
is

an

important

implicated

in

that

normal

He postulated

mediator
host

of

the

defense,

is

advantageous while the secreted TNF mediates the explosive clinical
syndrome.

Likewise, interferon-y (IFN-y), produced by T cells, seems

to work in synergism with TNF for cell cytotoxicity.
OKT3 and Lvmphokine Production
Because OKT3's first dose reaction was similar to lymphokine
induced clinical symptoms,
lymphokine

levels

were

investigators attempted to measure if
increased

after

OKT3

administration.

Suthanthiran (5) demonstrated that OKT3 added to peripheral blood
lymphocyte culture promoted an increase in the level of IL-2 and
IFN-y.
Abramowicz

(8)

studied

renal

transplant

received OKT3 for nonrejection prophylaxis.
was measured after exposure to OKT3

patients,

TNF did

undetectable.

not increase,

and

who

Lymphokine release

(with

prednisolone) or to cyclosporine at 6 mg/kg.

recipients

1 mg/kg

of methyl

In the cyclosporine

IL-2 and

IFN

levels were

In contrast, OKT3 induced a marked rise in IL-2 (peak

2 hr), IFN (peak 2 hr) and TNF (peak 1 hr).
these rises were transient.

Lasting only 24 hours,

Furthermore, in 78% of the OKT3 treated

patients, subsequent doses of OKT3 did not induce a significant
release of these lymphokines.
Meanwhile, Chatenaud (7), using 17 patients, showed that the
first, and only the first, dose of OKT3 caused a sharp increase of
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IFN-y and TNF-a.

In 3 patients who had received a haploidentical

graft from a family member and had not received steroids, IL-2 was
also increased.

The peaks of lymphokine levels were similar to the

previous study except that IFN and IL-2 both peaked at 4 hours.

The

rise in lymphokine levels resolved in 15-20 hours and did not recur
with the second dose.
at any time point.

No changes in IL-113 and IFN-a were detected
In an extension of the study to 35 patients,

similar results were obtained (6).
paralleled

temporally

the

This increase in lymphokines

reversible

clinical

syndrome.

The

difference in the two studies (6 and 8) which may explain the
different IL-2 levels is that Abramowicz used much lower doses of
steroids than Chatenoud (1 mg/kg vs 1g).
Bloemena (50)

has recently implicated

IL-6,

acute phase hepatic proteins, as another mediator.

an

inducer of

He suggested

that even though IL-6 levels are raised during rejection, they are
increased significantly more after OKT3.

Because the peak of IL-6

was 48 hours, he suggested that IL-6 could mediate some of the late
side effects associated with OKT3.
Multiple studies (50-54) have shown that all lymphokines are
elevated

during

rejection.

However,

the

level

of

circulating

lymphokines increases even more after OKT3 administration.
OKT3-Tcell

activation-Lvmphokines

Thus far, the ideas that OKT3 causes a first dose reaction, that
this reaction mimics the clinical picture of lymphokine release, and
that OKT3 causes an increase in lymphokine release (in vitro and in
vivo) have been discussed.

Other studies have indicated that T cells

■

11

are responsible for lymphokine production after activation by other
mitogens (55-58).

How does one resolve the conflicting evidence

that OKT3 is a powerful immuno-suppressant and that OKT3 induces
a release of lymphokines, products of T cell activation?
examining

blood

levels

of

lymphokines,

most

Prior to

investigators

(10,20,21,59,60,61,62) explained the adverse drug reaction to OKT3
as resulting from endogenous pyrogens which were released by
opsonized cells, lysed in the reticulo-endothelial system.

Some

problems with this theory include that other anti-T cell antibodies
which induce opsonization do not cause a similar syndrome and that
very

small

amounts

of

active

lymphokines

are

stored

within

lymphocytes.
Therefore, another mechanism was needed to explain how OKT3
induced a

lymphokine increase - OKT3

is not only a

powerful

immunosuppressant but also a T cell mitogen, capable of inducing
activation and proliferation.

In 1980, van Wauwe (63) showed that

OKT3 was a potent mitogen of peripheral
Measuring 3H thymidine incorporation as an
activation,

lymphocytes in vitro.
indication of T cell

he showed that OKT3 had definite mitogenic activity,

even greater than phytohemagglutinin (PHA) and concanavalin A (CON
A).

Furthermore, OKT3 displayed no inhibition of response at high

concentrations.
Von Wussow (64) demonstrated that T lymphocytes which
expressed CD3 antigen produced IFN after OKT3 was added to the
medium.

The timing

of maximum

activity

correlated with in vivo studies (4 hours).

of

IFN

(3-6

hours)

Chang demonstrated that a
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certain subset of T cells, CD4+ cells, secreted IFN (peak 3 hours) and
that macrophages played an accessory role.

Another study (65)

implied that OKT3 induced IL-2 and IL-2R production, while others
(66)

showed

Furthermore,

that

OKT3

Suthanthiran

induced
(5,13),

production

of

performing

in

TNF
vitro

mRNA.
studies,

demonstrated that OKT3 caused T cells to become activated, induced
both

secondary cytolytic activity and

natural

killer activity,

and

increased the levels of IL-2 and IFN.
Because most circulating blood cells are CD3- after OKT3 use,
Ellenhorn (67) examined lymph node cells and offered the first in
vivo support for T cell activation by OKT3.

OKT3 coated lymph node

T cells showed increased proliferation in vitro in presence of IL-2
and increased expression of IL-2R.

Several studies (4,68,69,70)

have demonstrated a requirement of macrophages for OKT3 induced
activation to occur.

Ceuppens (70) discussed a family which failed

to respond mitogenically to OKT3 but did respond to other mitogens;
this

lack

of

macrophages.

response

was

restored

with

the

addition

of

In contrast, others have demonstrated mitogenesis in

macrophage free media (5,63,64,66).
The

clinical

important role

setting

of OKT3

administration

in the amount of lymphokines

severity of the subsequent first dose reaction.

may

released

play

an

and the

When used in the

acute post-operative period, OKT3 may have different side effects
than

when

used

for

treatment

of

investigators found no difference(37).

rejection

-

although

some

Postulating that T cells had

not been activated by rejection, some researchers(34,39,71) implied
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that OKT3 used as prophylactic agent had fewer side effects.

Also,

the drug was often-times giving peri-operatively, and the patient,
under anesthesia, would have been unable to report some of the side
effects.

Others (25) believed that prophylactic use of OKT3 carried

increased risk for adverse drug reactions because there was no prior
exposure to immunosuppressants.
Concomitant immunosuppression plays an
cytokine

release from

Cyclosporine
activation(72),
inhibit

may

act

permit

production

T cells and

of

corticosteroids(51,75)

in

vitro

in

OKT3

to
T

both

(74)

inhibit

IL-1

related

inhibit

suppressor
IL-2

important role

cell

symptoms.

mitogen

directed

proliferation(73),

and

IFN

dependent

in

(75).

release

and
Also,

of

IL-2,

inhibit IFN release and have general lymphopenic effects (56,76,77)
- which would decrease the number of T cells exposed to OKT3.
Several

investigators

immunosuppressives
administration.

have

affect

examined

lymphokine

if

levels

concomitant
post

OKT3

Suthanthiran (5) has shown that cyclosporine and

methyl prednisolone caused a marked inhibition of memory T cell
proliferation and of cytotoxic lymphocyte activity.
was

markedly decreased by cyclosporine and

prednisolone;

both

equally

inhibited

release

investigator (6) determined that methyl

IL-2 production
mildly by

of TNF.

methyl
Another

prednisolone exerted

its

greatest effects in decreasing OKT3 related side effects if it was
given in high doses (500mg) 15-60 minutes prior to OKT3.
Gaston published a report (78) indicating the importance of
TNF as the cause of OKT3 related side effects.

Fie used a graded

■
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scale (0-3) for four symptoms (fever, headache, dyspnea, rigors).
Patients were separated into two groups, based on the number of
side effects reported.

The total number of CD3+ cells and of CD4+

cells prior to OKT3 administration were higher in the group with the
more severe reaction.

As with other studies, the peak of TNF at 2

hours correlated well with the severity of the reaction.
no rise in IFN or IL-2.

He showed

All patients were premedicated with 250 mg

of methyl prednisolone which could account for the lack of increase
in IL-2.

He postulated that T cell activation rather than lysis was

the cause of the increased levels of TNF and the subsequent adverse
reaction.
Based on the above mentioned studies, it is now thought that
OKT3 is a powerful immunosuppressant and it possesses immunoactivating abilities that are dose related.

Because CD3+ cells are

removed from circulation (by opsonization or modulation) and are
unable to react, lymphocyte activation, and hence clinical reaction
to OKT3, may not exist after the first or second dose of OKT3.
Murine Model
A murine model for OKT3 exists which further supports the
role of OKT3 as a mitogen, capable of stimulating
release and producing a symptom complex.

lymphokine

Immunizing Armenian

hamsters with murine cytolytic T cell clone, Leo (79) has developed
a monoclonal antibody (145-2c11) which is a murine analog to OKT3.
This monoclonal antibody is directed at the CD3e component of the
TCR/CD3 complex.
antigen

specific

It can act also as a T cell mitogen, inducing non¬
lysis

and

T cell

proliferation.

Hirsch

(80,81)

'
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classified further 145-2c11 actions, finding that it produced a rapid
depletion

of peripheral

T cells

and

a delayed

depletion of T cells in lymphoid tissue.
modulation

of

TCR

Immunosuppressive

and

a

incomplete

This antibody induced a

mitogenic

abilities of

and

response

145-2c11

were

in

T

cells.

demonstrated

by

increased graft survival time and decreased cytotoxic T lymphocytes
activity.

Because rapid and extensive lysis did not occur within the

first 2 days of therapy, the adverse drug reaction secondary to the
monoclonal antibody was probably not due to lysis.

They postulated

that this reaction may be secondary to the reactivation of latent
viruses as the adverse drug reactions did not appear in hepatitis
free mice.

This monoclonal antibody also caused IL-2R expression,

IL-2 secretion, and extra-medullary hematopoiesis in the spleen.
Others (82-85) utilized this monoclonal antibody to address
further the issue of OKT3 promoting lymphokine release, a proposed
cause of the first dose reaction.

In vivo injection of 145-2c11

in

mice caused a transient increase in TNF, IFN, IL-2, IL-3, and IL-6
that

paralleled

diarrhea,

a

symptom

hypomotility,

complex

consisting

piloerection,

of

and

hypothermia,
somnolence.

Histopathology included cell necrosis and edema in lymphoid organs
and edema/congestion of lung, liver and Gl tract.

Serving as a

control, anti-CD4 antibodies did not elicit a lymphokine release or
the clinical picture.

These studies helped link the clinical reaction

to the release of lymphokines because the kinetics of increased
lymphokines were

superimposable

with

the

clinical

picture,

the
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kinetics were similar to OKT3, and the reaction was similar to that
described after lymphokine administration.
Prevention of First Dose Reaction
In an attempt to prevent the first dose reaction to OKT3,
various protocols have been implemented.
included

pretreatment

diphenhydramine,

30

minutes

acetaminophen,

and

Many protocols have

prior

to

OKT3

glucocorticoids.

with
Some

protocols also require glucocorticoids (100 mg hydrocortisone) 30
minutes after OKT3 use.
potential

protective

However, no study has analyzed the

effects

of

the

different

protocols

incidence or severity of OKT3 induced side effects.
anticipate

that

drugs

which

inhibit

lymphokine

on

the

One would
release

after

lymphocyte activation might be useful in blocking this reaction.
Calcium Entry - A Step in T Cell Activation
One

might

postulate that if more were known about the

mechanism of OKT3

induced

mitogenicity,

treatment to inhibit the side effects.

one could develop a

Tsien (86) helped introduce

the potential role of calcium as an important mediator of T cell
activation.
the

He developed a technique (Quin 2) to measure directly

intracellular calcium

concentration

in

mitogen

cells, which showed a 2 fold increase in calcium.

stimulated

T

Calcium free

medium and agents that increased cAMP, which were both known to
inhibit mitogenesis, inhibited this calcium response.
In a review of the role of calcium in lymphocyte proliferation
(87), Lichtman discussed that calcium uptake by the cell occurred
after mitogen stimulation, which lead to 3H thymidine uptake in the
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DNA and subsequent mitosis.

This activation effect was blocked by

EGTA, a calcium chelator.

Furthermore, the calcium ionophore

A23187 induced both calcium and 3H thymidine uptake and served as
a T lymphocyte mitogen.
association

between

Mills (88,89), also using Quin 2, showed an

phytohemagglutinin

(PHA)

induced

calcium

uptake by cell and 3H thymidine uptake by DNA; both were blocked by
EGTA, as was PHA induced IL-2 production.

He concluded that T cell

mitogenesis did not occur without an initial calcium flux.
Mitogens such as PHA and concanavalin A (con A) may require a
calcium flux for T cell activation, but does OKT3?
have

suggested

that OKT3

intracellular calcium.

promoted

a

Researchers(2)

significant

increase

in

Using a CD3 negative (CD3-) culture, they

also demonstrated that the calcium ionophore could obviate the need
for the CD3 antigen in producing mitosis.

Because normal mitogens

(PHA) did not cause an increase in intracellular calcium in CD3cells, the researchers linked mitogenesis to increased calcium and
CD3 transduction of signal.

Oettengen (4) speculated that one of the

3 chains of the CD3 complex was the actual calcium channel and that
the antigen-bound TCR served to activate this calcium channel.

He

also showed that OKT3 induced an intracellular increase in calcium
which was dependent upon extracellular calcium, was sensitive to
membrane polarization, and was blocked by lanthanum, a calcium
channel blocker.
Calcium Channel Blockers - Inhibition of T Cell Activation
Several

studies

have

examined

whether

calcium

blockers are effective in inhibiting T cell activation.

channel

Gearing (90),
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using 3H thymidine uptake as measure of proliferation in rat blast
cells and in a murine T cell clone, demonstrated that both verapamil
and

nifedipine

proliferation.

at

doses

G rie r(91),

of

10

using

ug/ml
con

inhibited
A

to

IL-2

induced

stimulate

bovine

retropharyngeal lymphocytes, showed that verapamil inhibited 3H
thymidine incorporation in a dose dependent manner (20% at 2 uM,
40% at 10 uM, and 60% at 20 uM).

Another study, by McMillan(92),

showed, that at doses more than 10 uM, verapamil inhibited murine T
cell proliferation to alloantigen and con A.
Other studies, using peripheral blood mononuclear cells from
healthy volunteers, have analyzed the effects of calcium channel
blockers on human T cell activation.

Larson

(93) showed that

verapamil at 10 ug/ml inhibited IL-2 induced 3H thymidine uptake by
20%, whereas the maximal inhibition was seen at 60 ug/ml.
(94),

Walz

using phytohemagglutinin and phorbol myristate acetate as

mitogens, demonstrated that verapamil required levels of at least
30 uM to have inhibiting effects on 3H thymidine uptake, calcium
influx, and levels of IL-2 mRNA.

Birx(95) determined the dose of

three calcium channel blockers required to produce a 50% inhibition
to con A (verapamil at 15 uM, nifedipine at 24uM, and diltiazem at
80 uM).

Furthermore, Weir (96), varying doses of verapamil at 0.5

uM, 5 uM and 50 uM, demonstrated an inhibition of mRNA production
at 3%, 24% and 84%, respectively, and an inhibition of new protein
synthesis at 0%, 14% and 61%, respectively.
Therefore, it appears that calcium channel blockers inhibit T
cell

mitogenesis

in

vitro

in

a

dose

dependent

manner.

The

.
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therapeutic plasma concentration for each of the three calcium
channel blockers (verapamil, nifedipine, and diltiazem) is less than
200 ng/ml, or less than 0.5 uM (94,97,99-103).

This level is less

than the in vitro level shown in the previous studies to inhibit T cell
mitogenesis.

Weir (97) addressed the question of whether OKT3

stimulation of T cells was similarly affected.

He incubated a

culture of peripheral blood mononuclear cells from healthy adult
donors with 3 ug/ml of OKT3 for 3 days.

In a dose dependent

fashion, verapamil inhibited OKT3 induced T cell proliferation by
22% at 0.5 uM, 30% at 5 uM, and 76% at 50 uM.
Madreoli (98) studied the immunological status of renal graft
recipients who received calcium channel blockers for one month.
The patients chosen for the study had shown no signs of rejection,
nephrotoxicity

nor

viral

infection

and

had

been

on

an

immunosuppressive therapy consisting of cyclosporine. He suggested
that calcium channel blockers inhibited the mitogenic response to
PHA and promoted an increase in CD8+ cells. More importantly, he
used therapeutic doses of Nicardipine (60mg/day) and Diltiazem
(90mg/day).

Because the calcium channel blockers caused no change

in the non calcium dependent poke weed mitogen, he concluded that
calcium channel blockers work by blocking a calcium channel
necessary for T cell activation.

Madreoli implied that calcium

channel blockers may inhibit T cell activation at normal therapeutic
doses.
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Purpose
To determine whether clinically used doses of calcium channel
blockers are effective in ameliorating first dose reactions to OKT3.
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Methods
A retrospective study was performed on all renal transplant
patients who had received OKT3 between December 1983 (when OKT3
became

available)

and

July

1990

(when

this

analysis

began).

Transplantation flow sheets (a daily record of a patient's hospital
course) and discharge summaries were used to determine which
patients had received OKT3 and the reason for its use.
population is described in Table 1.

The patient

Pediatric cases were excluded

from the study because this patient group may not reliably report
symptoms.
The patients received OKT3 either to treat resistant rejection
(19 in calcium channel blocker group vs 42 in control) or to avoid
cyclosporine toxicity in the setting of delayed graft functioning (1
in

calcium

channel

blocker

group

versus

7

in

control).

Administration of OKT3 (5mg/day intravenously) was preceded 30
minutes by acetaminophen (650 mg), diphenhydramine (25-50 mg),
and corticosteroids.

Some patients (N=31) received hydrocortisone

100 mg 30 minutes after OKT3.

Because of the incidence and

severity of first dose reactions, a physician administered the OKT3
while a nurse monitored for a reaction.
The

hospital

records

were

studied

for

demographic

information, including age, sex, race, days of OKT3 therapy, and days
post-op from transplant until OKT3 was given.

Dialysis was defined

by the patient undergoing dialysis (hemo or peritoneal) 1 day prior to
OKT3

or up to

2 days after OKT3 was

immunosuppressives,

including

begun.

azathioprine,

Concomitant

cyclosporine,

and
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glucocorticoids,

were

recorded.

Glucocorticoid

doses

were

converted to methyl prednisolone equivalents using the following
formula (4mg methyl prednisolone = 5 mg prednisone = 20 mg
hydrocortisone).
The signs and symptoms of first dose reactions following the
first 48 hours of OKT3 were recorded for each patient, and the
definitions used are included in Table 2.

The signs and symptoms

analyzed in this study were chosen for their generally accepted
occurrence after the first dose of OKT3 in studies that included
more than 30 patient episodes (20,22,25,27,34,38,43,44).
Most of the information was obtained from the progress notes
of the attending surgeons, the residents, and the nurses.

Presence of

fever, changes in blood pressure, tachycardia, emesis, and diarrhea
were also checked on the nurses flow sheets.

Trough blood levels of

cyclosporine were obtained from a Chemistry Lab Data Sheet.

The

actual dosage and timing of all the medications were determined
from the nursing record of drug administration.
The data were then analyzed to determine whether first dose
reactions were less severe in those on calcium channel blockers
(N=20) versus those off (N=49).

To be included in the calcium

channel blocker group, a patient had to be on calcium channel
blockers for at least 3 days prior to the initiation of OKT3.
were

receiving

calcium

hypertension and angina.

channel

blockers

for

the

Patients

treatment

of

These patients did not receive calcium

channel blockers for the treatment of rejection or for the prevention
of reaction to OKT3.

The number who received each type of calcium
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channel blocker, the mean dose, and the range of doses are as
follows : (Nifedipine : N=13, mean dose 66.2mg, range 30-120mg;
Verapamil : N=5, mean 248mg, range 120-480mg; Diltiazem : N=2,
mean 135mg, range 90-180mg).

Patients receiving PRN nifedipine

for hypertension (N=4) were not included in the calcium channel
blocker group unless the total dose was greater than 30mg per day.
Statistics
All data were analyzed using chi-square analysis and Student
T-tests with a SAS statistical program.

The cyclosporine doses

were compared also with Wilcoxon Rank-Sum test.

These statistical

tools were employed after consultation with bio-statisticians from
Yale University School of Epidemiology and Public Health.
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Results
At the time of OKT3 administration,

20 patients were

calcium channel blockers and 49 were not (Table 3).

on

There were no

significant differences between the two groups in age, sex, race,
percent cadaveric transplants, and percent on dialysis.

At the time

of OKT3 administration, the dose and level of cyclosporine, the dose
of azathioprine, and the dose of glucocorticoid were not different in
the two groups.
Table 4 shows the percentages of the symptoms present in the
two groups.

Nearly 90% of each group developed fever.

The peak

temperature in the patients on calcium channel blockers was 102 ±.
0.3°F (range 99.3-104.4) which was identical to the peak in those
not on calcium channel blockers, 102 ±. 0.2°F (range 98.8-105.0).
Chills,

gastrointestinal

symptoms,

hemodynamic change were

respiratory

similar in

both

complaints,

groups.

and

Symptoms

relating to lethargy and fatigue were the only ones that did differ
between

the

two

groups,

occurring

twice

as

frequently

in

the

calcium channel blocker group.
Five patients received OKT3 on two different occasions, once
on calcium channel blockers at the time OKT3 administration and
once off.

In general, each patient had similar reactions to the OKT3,

regardless of presence of calcium channel blockers.

.
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Discussion
A powerful immunosuppressant, OKT3 monoclonal antibody is
used primarily to treat steroid resistant rejection or to protect the
kidney from cyclosporine toxicity in the setting of post-transplant
delayed graft functioning.
often

accompanied

The first and second doses of OKT3 are

by adverse

reactions,

nuisance to life threatening sequelae.

ranging

from

a

mild

Various cytokines, namely

TNF, IL-2, IFN, rise after OKT3 administration, in parallel with the
appearance of the clinical syndrome.

Because OKT3 has been shown

to be a T cell mitogen, these cytokines are believed to be the product
of T cell activation/proliferation, rather than T cell lysis.

Calcium

has been shown to be an important mediator of T cell activation
after OKT3, and calcium channel blockers decrease T cell activation
in vitro after stimulation with mitogens, including OKT3.

This study

attempted to determine whether clinically used doses of calcium
channel

blockers

could

effectively

decrease

the

symptoms

associated with the use of OKT3.
The frequencies of signs and symptoms of first dose reaction
to OKT3 observed in this study are similar to the frequencies found
by

other

investigators

patients were
including

(20,22,25,27,34,38,43,44).

not previously

immunosuppressive

administration,

were

similar

randomized,
regimens
in

the

two

at

Even

though

patient demographics,
the

time

groups.

of

OKT3

This

study

demonstrated that calcium channel blockers apparently offer no
protection against the first dose reaction of OKT3.

Analysis of peak

temperature showed no difference between the two groups.
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The reason why calcium channel blockers caused more fatigue
is not clear.

All calcium channel blockers can cause fatigue, which

is usually tolerated with subsequent doses.

There was no reason to

suspect

two

an

inherent

difference

in

the

perception of or reporting of fatigue.

groups

regarding

Furthermore, because

different symptoms/signs were analyzed with

significance

16

looked

for at P=0.05 level, there is a high likelihood that one of the factors
would be significant purely based on chance.
What are the possible explanations for the lack of a protective
effect

of

calcium

reactions?

channel

Firstly,

blockers

clinically

used

against
doses

first

of

dose

calcium

OKT3
channel

blockers may not achieve high enough blood levels to inhibit OKT3
induced T cell activation.

The therapeutic plasma concentration for

each of the three calcium channel blockers (verapamil, nifedipine,
and

diltiazem)

(94,97,99-103).

is

less
In

than

all the

200

ng/ml,

or

less

than

0.5

in vitro studies (90-95) which

uM
used

mitogens other than OKT3, the levels of calcium channel blockers
required to

inhibit T cell

proliferation

were

substantially

than the normal therapeutic level of 0.5uM by 1
magnitude (5uM to 50uM).

higher

to 2 orders of

Several studies (94,95) demonstrated no

inhibition at 0.5 uM while the others did not test at concentrations
this low.

The only in vitro study using OKT3 as the T cell mitogen

(96) did show a 22% inhibition of T cell activation at 0.5 uM of
verapamil.

However, it is possible that such a small degree of

inhibition, if it also occurs in vivo, is not sufficient to decrease the
signs and symptoms related to lymphokine release.

Because our

•

•
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patients had received typical doses of calcium channel blockers for
at least three days prior to receiving OKT3, blood levels, although
not directly measured, were assumed to be in the therapeutic range.
In vitro studies using OKT3 as the T cell mitogen should be repeated
to

determine

if

levels

of

calcium

channel

blockers

achieved

therapeutically (ie. less than 200 ng/ml) inhibit T cell proliferation.
As always, however, the in vitro work may not be directly applicable
to clinical settings.
Not all calcium channels blockers possess the same qualities.
Carteza (104) studied the effects of calcium channel blocker on in
vivo delayed type hypersensitivity in mice.
the

antigen

oxazolone,

Sensitizing mice with

he found that nifedipine

suppressing effects, verapamil
and diltiazem had no effect.

had

significant

had significant enhancing

effects,

Because the total number of patients on

calcium channel blockers in this present study was small, the effect
of the

three

individual

calcium

channel

blockers

could

not

be

analyzed separately.
As

the

study

was

retrospective,

the

patients

randomized prospectively to calcium channel blockers.

were

not

The patients

received calcium channel blockers for the treatment of hypertension
and angina.

The patients did not receive the blockers

for the

treatment of rejection or for the protection against the first dose
reaction to OKT3.

Some patients in the control group who had angina

or hypertension were treated with different agents.

The data were

not examined to determine if the underlying indication for calcium
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channel blockers could be responsible for the lack of any observable
differences.
In this study, five patients received OKT3 twice, once on
calcium channel blockers and once off them.

Albeit a small number

to analyze, there was no discernable difference in the side effects
for each individual patient for the two different episodes.

For each

patient, the second episode of OKT3 caused a reaction that was
similar to the first episode.

The individual results in these five

patients, with each one serving as his/her own control, strongly
support our final conclusion about the absence of protection with
calcium channel blockers.
The number of patients in this study was relatively small.
Only 69 patient episodes of OKT3 could be found over a 6.5 year span,
with an uneven distribution (20 on calcium channel blockers vs 49
controls) between the two groups.
evenly

distributed

sample,

a

Perhaps with a larger, more

different

result

would

bear

out.

However, the data does not suggest that there was even a tendency
toward a less severe reaction in our patients on calcium channel
blockers.
Our study was a retrospective one.

Because of the small

number of patients receiving calcium channel blockers over the
relatively long time frame, we had to chose this method.
because

the

nurses

and/or

the

intern

closely

However,

monitors

the

hemodynamics and the temperature during the first few hours and
because more objective symptoms such as vomiting/diarrhea are
generally recorded by nurses on a daily flow sheet, these symptoms
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were likely to be adequately recorded.
reason

to

suspect observer or

In addition, there was no

recorder

bias

in

either

group.

Although a prospective study would have allowed more detailed
analysis of each sign and symptom, it is likely that the final result
would be the same.
Koch-Weser (105) has pointed out that adverse drug reactions
can be very ambiguous events, promoting widely divergent responses
from

clinical

pharmacologists.

One

must first determine

if an

actual drug reaction is the proper etiology of the symptoms (as
opposed to an illness) and then determine which drug caused it. In
our patient population, not only are multiple disease states present
(transplant,

post-op,

multiple drug regimens.

hypertension,

rejection,

etc)

but

so

are

However, because reaction to OKT3 occurs

so frequently and with a recognizable clinical syndrome, OKT3 is
probably responsible for the clinical syndrome experienced by our
patients.

Because OKT3 induced side effects occur only with the

first doses, reproduction of the syndrome with OKT3 rechallenge is
difficult.

However, as mentioned previously, the 5 patients who had

received OKT3 (while on calcium channel blockers and while off
them) had similar reactions both times.
In order to improve upon both reproducibility and validity, it is
important

to

use

symptom(106-108).
explicit

criteria.

explicit

criteria

for

inclusion

of

a

sign

or

As noted in the methods, this study did use
However,

the

adverse

drug

reactions

were

determined by one person (should be multiple) and at one time (if
same person, should be repeated at later date).

Because the
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incidence of side effects in this study is similar to that reported in
other studies,
means

it is likely that retrospective studies are a valid

of testing

for

OKT3

associated

side

effects

if

explicit

criteria are used (105-108).
In summary, in our study, calcium blockers did not protect
against first dose reactions to OKT3.
account

for this

result

is

that

The

clinically

best explanation to

used

calcium

channel

blockers do not attain a high enough serum level to inhibit OKT3
induced T cell activation.
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Table 1

Patient .Population

Category
Number of Ppis,Q.cle.s
Transplant recipients (1983-1990)
224
OKT3 episodes(a)
80
Files not used(b)
-11
OKT3 episodes in study
69
Episodes on calcium channel blockers
20
Episodes not on calcium channel blockers
49
(a) An episode of OKT3 use (to treat rejection or used
prophylactically to prevent cyclosporine toxicity in the early
post transplant period)
(b) 2 files not found, 1 confidential file, 5 pediatric cases,
3 pancreas/kidney recipients

Table 2

Definitions of Signs and Symptoms

Fever - Temperature > 100 F in first 48 hours with negative cultures
Chills - Complaint of chills, rigors
Dyspnea - Complaint of shortness of breath, trouble breathing
Wheeze - Complaint of wheeze, or noticed on physical exam
Chest pain - Complaint of chest pain or chest tightness
Emesis - Presence of vomiting
Diarrhea - Presence of diarrhea
Headache - Presence of headache
Seizure - New onset of seizure and witnessed by med staff
Malaise - Complaint of lethargy, extreme fatigue
Aseptic meningitis - Lumbar puncture showing white blood cells in
cerebral spinal fluid with negative cultures
Tachycardia - Heart rate > 100
Hypotension - Systolic < 90 or decrease in systolic > 20 mm Hg
Hypertension - Systolic > 160 or increase in systolic > 20 mm Hg
Arthralgia - Complaint of joint aches/pains
Myalgia - Complaint of muscle aches/pains

Table 3

Comparison of Demographic Data

Calcium, Channel Blocker
Variable
Sex (% Male)
Age (years) (a)
Race (% Black)
Transplant Type
(% cadaver)
Dialysis (b)
Days post transplant (c,d)
CSA Dose (mg/day)Day Before (a)
CSA Level (ng/ml)Day Before (a)
CSA Dose (mg/day)Day of OKT3 (a)
CSA Level (ng/ml)Day of OKT3 (a)
Imuran dose (mg) (a)
Solumedrol dose (mg)
(24 hour before OKT3) (a)
Solumedrol dose (mg)
(1 hour before OKT3) (a)
a
b
c
d

Control

(N=20)

(N=49)

51
37.3 ± 2.9
1 5
90

70
36.8 ± 1.8
1 8
78

45
27 (0-1874)
485.5 ± 87

49
21 (0-995)
342.2 ± 61

118.3 ± 33

81.8 ± 15

390.0 ± 81

239.0 ± 49

124.7 ± 31

114.8 ± 21

11.8 ± 6.8
301.9 ± 90

17.3 ± 6.0
271.1 ± 34

104.4 ± 31

134.3 ± 25

Mean ± standard error of mean
Percent of patients on dialysis
Days after transplant when OKT3 was started
Median (Range)

Table 4

Signs and Symptoms of First Dose Reaction to OKT3(a)

Calcium Channel Blocker
(N=20)

Control
(N=49)

Siqn/Svmptom(b)

Percent(c)

Percent(c)

Fever
Malaise
Chills
Tachycardia
Emesis
Hypertension
Diarrhea
Myalgia
Hypotension
Arthralgia
Headache
Dyspnea
Wheeze
Chest Pain/Tightness
Aseptic Meningitis
Seizure

90
70 *
60
50
50
45
40
35
30
30
25
25
20
15
10
0

88
33
41
51
35
45
45
1 6
23
1 6
43
23
8
1 4
4
0

*
a
b
c

P < 0.005 by chi-square analysis
Within first 48 hours
Criteria for each sign/symptom is listed in Table 2
Percent in each group with a given sign or symptom
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